Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure.
about
Critical Questions about PARADIGM-HF and the FutureRole of estrogen in diastolic dysfunctionPotential new drug treatments for congestive heart failure.Silent disease progression in clinically stable heart failure.Innovative Therapeutics: Designer Natriuretic Peptides.Protein kinase G I and heart failure: Shifting focus from vascular unloading to direct myocardial antiremodeling effects.Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF).Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones: biomarkers or mediators.Mas receptor mediates cardioprotection of angiotensin-(1-7) against Angiotensin II-induced cardiomyocyte autophagy and cardiac remodelling through inhibition of oxidative stress.Cardiorenal fibrosis and dysfunction in aging: Imbalance in mediators and regulators of collagen.Depressed Corin Levels Indicate Early Systolic Dysfunction Before Increases of Atrial Natriuretic Peptide/B-Type Natriuretic Peptide and Heart Failure Development.Aging and the cardiac collagen matrix: Novel mediators of fibrotic remodellingCurrent treatment of heart failure with preserved ejection fraction: should we add life to the remaining years or add years to the remaining life?The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment.Time and technology will tell: the pathophysiologic basis of neurohormonal modulation in heart failure.Rationale and therapeutic opportunities for natriuretic peptide system augmentation in heart failure.LCZ696 (angiotensin-neprilysin inhibition): the new kid on the heart failure block?Angiotensin II Receptor Blocker Neprilysin Inhibitor (ARNI): New Avenues in Cardiovascular Therapy.New medical therapies for heart failure.Sacubitril/valsartan (LCZ696) for the treatment of heart failure.Molecular Physiology of Membrane Guanylyl Cyclase Receptors.New Novel Treatment Approaches for Heart Failure With Reduced Ejection Fraction.An evidence-based review of recent advances in therapy for heart failure with reduced ejection fraction (HFrEF).Hypertension in Patients with Heart Failure with Reduced Ejection Fraction.Cardiac fibrosis in the ageing heart: contributors and mechanisms.Treatment Approaches to Congestion Relief in Acute Decompensated HF: Insights After DOSE-AHF and CARRESS-HF.Sacubitril/ValsartanPARADIGM-HF: Have we achieved a new paradigm in the treatment of heart failure?Enhanced heart failure, mortality and renin activation in female mice with experimental dilated cardiomyopathy.Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure.Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure.LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone.
P2860
Q26741029-9D5B8C4D-A4A4-4378-9155-B597C23D591CQ27026798-27FA4FFE-4D70-41E6-BF40-D3FAA23B18C6Q30251531-90F11B91-BF94-4C6A-99B2-489126A07B3BQ33578212-E525862C-C35E-4E52-BD53-3EC8D80F0E64Q33653332-F25079C1-9018-4056-93F3-F8D55B2ECAD3Q34421211-EA1097B2-837A-45DB-A71A-8CD1900F2522Q35035016-DAE578B1-9E24-4D7F-A06D-67347197CBDFQ35164124-672F4AD7-7C76-4A8F-BD3F-0F3B209FCEB3Q36476862-8BF6FA2B-290F-45BC-B448-4092B158B9AEQ36584049-96370760-16E8-42E3-8CEE-82A1129C25A8Q36683746-8E599662-6992-4113-B105-F3669A5B527AQ37096257-E9400D9A-48ED-4B57-8715-9A4ED402A4A9Q37292234-07DBBB97-EB2D-4870-925B-D7DDD56BE995Q37583865-26660FF5-DDEC-4593-A8F8-B3566FE9E611Q38248810-4FAB096C-4D88-4B00-90E0-B7F3A20ED142Q38261513-B034B7CC-0932-4915-AC8A-0639E7B67448Q38416785-9907FFA9-FB8A-42EA-8B00-466BA3CDFCCDQ38534772-06BB5FAF-7F7F-42BF-95B4-E2E68891332DQ38594785-BD5364CE-F5A2-4EA2-B9B1-C7FBC40B87CDQ38661061-4C3E8E14-F227-4190-A7B7-113F13E2BC77Q38794203-486F3BF1-5C05-44D0-B82D-D566BFEDACEDQ38837866-7F4500E9-A7D8-4972-8A8E-20E89D940583Q38973132-F516CD62-7C28-4B95-B0FD-B395B7BE523BQ38994796-AC73C02D-61B5-4B46-AF2C-2C443F050FD4Q39186232-CFCA984A-62C4-4BED-AB52-9AC5C98128F2Q39203291-23C4B36D-4F37-4203-B774-71503EFB7228Q42564219-647B1491-E874-41F1-A076-FF65D2A642D6Q43179583-C987D4DD-B55C-4814-9CB8-BE07BEDA122BQ47159762-51312B5D-8A96-44A6-925D-5F8B26818DD4Q47855200-66173427-8883-4D5B-9D1D-2B830594FA53Q49914014-192D968A-1608-4CBA-BE9D-C4FA6A54928EQ53586435-6116CA20-F81F-4700-8285-C688470CFFEE
P2860
Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Renin-angiotensin blockade com ...... cepts to combat heart failure.
@en
Renin-angiotensin blockade com ...... cepts to combat heart failure.
@nl
type
label
Renin-angiotensin blockade com ...... cepts to combat heart failure.
@en
Renin-angiotensin blockade com ...... cepts to combat heart failure.
@nl
prefLabel
Renin-angiotensin blockade com ...... cepts to combat heart failure.
@en
Renin-angiotensin blockade com ...... cepts to combat heart failure.
@nl
P2093
P2860
P1476
Renin-angiotensin blockade com ...... cepts to combat heart failure.
@en
P2093
Andrew R Kompa
Bing H Wang
John C Burnett
S Jeson Sangaralingham
Thomas G von Lueder
P2860
P304
P356
10.1161/CIRCHEARTFAILURE.112.000289
P577
2013-05-01T00:00:00Z